Cancer trials numbered 2,182 in Africa versus 49,054 in the United States, a 22x gap, while cardiovascular research showed 1,426 versus 19,566 (14x).
Regional Comparison
Cancer — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Biomarker: AF 1,149 vs US 15,494 (13.5x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Africa's clinical trial portfolio is structurally misaligned with its disease burden. While infectious diseases account for 52% of DALYs and receive 72% of trial investment, non-communicable diseases (cardiovascular, cancer, diabetes) cause 37% of DALYs but attract only 15% of trials. This diseasome mismatch means the conditions increasingly killing Africans — the epidemiological transition — are the least studied on the continent.
The Evidence 138 words · target 156
In global health systems, does the alignment between disease burden and clinical trial investment reveal a systematic mismatch in Africa? This cross-sectional analysis compared condition-specific trial volumes to WHO disability-adjusted life year estimates across Africa (23,873 trials) and the United States (190,644) using ClinicalTrials.gov API v2. Investigators reported the burden-to-trial ratio per condition as the primary estimand. Cancer trials numbered 2,182 in Africa versus 49,054 in the United States, a 22x gap, while cardiovascular research showed 1,426 versus 19,566 (14x). Mental health had only 174 African trials against 2,996 American trials, a 17x disparity. Only malaria (531 African versus 125 American trials) showed Africa leading the global research effort. These findings reveal that Africa's trial portfolio is misaligned with its epidemiological transition toward non-communicable diseases. Interpretation is limited by the indirect mapping between trial conditions and DALY categories.
Sentence Structure
Question
In global health systems, does the alignment between disease burden and clinical trial investment reveal a systematic mismatch in Africa?
Dataset
This cross-sectional analysis compared condition-specific trial volumes to WHO disability-adjusted life year estimates across Africa (23,873 trials) and the United States (190,644) using ClinicalTrials.gov API v2.
Method
Investigators reported the burden-to-trial ratio per condition as the primary estimand.
Primary Result
Cancer trials numbered 2,182 in Africa versus 49,054 in the United States, a 22x gap, while cardiovascular research showed 1,426 versus 19,566 (14x).
Robustness
Mental health had only 174 African trials against 2,996 American trials, a 17x disparity.
Interpretation
Only malaria (531 African versus 125 American trials) showed Africa leading the global research effort.
Boundary
These findings reveal that Africa's trial portfolio is misaligned with its epidemiological transition toward non-communicable diseases.